Supplementary information:

Hepatomas are exquisitely sensitive to pharmacologic

ascorbate (P-AscH⁻)

Xuan Zhang^{1, #}, Tiefu Liu^{1, #}, Zehuan Li^{2, #}, Yanling Feng¹, Christopher Corpe³, Shanshan Liu¹, Jingpu Zhang¹, Xiaomeng He¹, Feng Liu¹, Li Xu¹, Longqiang Shen¹, Shun Li¹, Qianlin Xia⁴, Xiuhua Peng¹, Xiaohui Zhou¹, Weiping Chen⁵, Xiaoyan Zhang¹, Jianqing Xu¹, Jin Wang^{1, *}

¹Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jinshan District, Shanghai 201508, China; ²Department of General Surgery, Zhongshan Hospital, Fudan University, 200032, Shanghai, China; ³King's College London, London, Nutritional Science Department, 150 Stamford street, waterloo, London, SE19NH, United Kingdom; ⁴Department of Laboratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; ⁵Genomics Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

[#] These authors contributed equally to this work

*Corresponding Author: Jin Wang, Ph.D.
Scientific Research Center,
Shanghai Public Health Clinical Center,
Fudan University,
2901 Caolang Road, Jinshan District, Shanghai 201508, China;
Ph: 86-21-57036495; Fax: 86-21-57247094
Email: wjincityu@yahoo.com

1. Supplemental Tables.

| aPCR | |
|------|--|
| | |

| Nama of gapog | Sequences of Primers (5'-3') | | | |
|---------------|------------------------------|-----------------------|--|--|
| Name of genes | Forward | Reverse | | |
| CDK4 | ATGGACGTCTGTGCCACATC | CACGGGTGTAAGTGCCATCT | | |
| CDK6 | ACAGTGTCACGAACAGACAG | CAAGACTTCGGGTGCTCTGTA | | |
| c-Myc | CCTTCTCTCCGTCCTCGGAT | TGCTGATGTGTGGAGACGTG | | |
| Casp3 | ATGTCGATGCAGCAAACCTC | CCAGTTCTGTACCACGGCAG | | |
| AGER | GCCACTGGTGCTGAAGTGTA | CACGGACTCGGTAGTTGGAC | | |
| DGKK | TGAAGGAAGGACCTATGCTGA | ATGTCTTTCCGGTTGGGTGC | | |
| ASB2 | ACCTGGACTGTCTCCTGTCA | TTGGATTCCACCTTGGCTCC | | |
| TCP10L2 | TGGATGCCTTGAGGAAGCAG | AGTCGCACTCTGACTCTTGC | | |
| Lnc-ALCAM-3 | AGACCATGCTCCTTCCACAT | TAAAGCTGCCAACAACTCCG | | |
| Inc-TGFBR2-1 | GGCATGGACAGATCTCATTGG | GGGAGAGTCTTGAGCTTGGT | | |
| 18S | GTAACCCGTTGAACCCCATT | CCATCCAATCGGTAGTAGCG | | |

| Proheset ID ConsNeme | | Fold-Change(H | p-value(H |
|----------------------|-----------------|---------------|-----------|
| Probeset ID | Genervame | vs. N) | vs. N) |
| NM_001206954 | AGER | 10.14 | 0.049 |
| ENST00000522882 | ENST00000522882 | 9.52 | 0.042 |
| Inc-DLEU1-1:1 | lnc-DLEU1-1 | 9.44 | 0.029 |
| Inc-ALCAM-3:1 | Inc-ALCAM-3 | 5.45 | 0.044 |
| Inc-TGFBR2-1:1 | Inc-TGFBR2-1 | 4.47 | 0.033 |
| NM_001242473 | C16orf97 | 4.18 | 0.023 |
| ENST00000593792 | ENST00000593792 | 3.85 | 0.040 |
| NM_001013742 | DGKK | 3.60 | 0.030 |
| NM_014858 | TMCC2 | 3.59 | 0.038 |
| TCONS_12_00009686 | XLOC_12_005187 | 3.59 | 0.029 |
| NM_000815 | GABRD | 3.58 | 0.031 |
| NM_001322 | CST2 | 3.54 | 0.023 |
| Inc-BTF3L4-2:1 | lnc-BTF3L4-2 | 3.48 | 0.032 |
| XR_246983 | LOC101927345 | 3.42 | 0.021 |
| ENST00000544271 | BAD | 3.42 | 0.032 |
| NM_001452 | FOXF2 | 3.37 | 0.038 |
| NM_152450 | FAM81A | 3.33 | 0.049 |
| NR_125797 | ZFPM2-AS1 | 3.30 | 0.030 |
| ENST00000564702 | ENST00000564702 | 3.29 | 0.039 |
| NR_040093 | STARD4-AS1 | 3.24 | 0.036 |
| Inc-RNF38-2:1 | lnc-RNF38-2 | 3.23 | 0.024 |
| NM_002023 | FMOD | 3.20 | 0.028 |
| NR_003191 | GGTA1P | 3.17 | 0.044 |
| ENST00000541749 | LOC101929027 | 3.08 | 0.036 |
| AK022058 | AK022058 | 3.02 | 0.043 |
| NM_001024457 | RGPD1 | 2.97 | 0.041 |
| XR_424822 | LOC101929494 | 2.94 | 0.036 |
| Inc-KIF20B-1:3 | lnc-KIF20B-1 | 2.93 | 0.026 |
| NM_178826 | ANO4 | 2.83 | 0.021 |
| NR_110565 | MCM3AP-AS1 | 2.81 | 0.040 |
| NM_173662 | RNF175 | 2.79 | 0.041 |
| NR_046575 | MAGI1-AS1 | 2.78 | 0.036 |
| NM_001184746 | PAFAH1B2 | 2.78 | 0.031 |
| NM_004982 | KCNJ8 | 2.77 | 0.044 |
| NR_003072 | SNORD91A | 2.74 | 0.049 |
| lnc-C1orf86-1:2 | lnc-C1orf86-1 | 2.73 | 0.044 |
| NM_021992 | TMSB15A | 2.69 | 0.023 |
| NM_000541 | SAG | 2.66 | 0.047 |
| XR_424301 | LOC101929584 | 2.66 | 0.048 |

1.2. Table S2. 192 differentially expressed genes were only in High dose of ascorbate treated HCC.

| NM_030949 | PPP1R14C | 2.66 | 0.046 |
|----------------------|--------------------|-------|-------|
| NM_001190972 | C8orf88 | 2.65 | 0.018 |
| NR_028371 | FAS-AS1 | 2.64 | 0.025 |
| lnc-TRAF5-4:1 | Inc-TRAF5-4 | 2.61 | 0.033 |
| NM_172006 | WFDC10B | 2.59 | 0.029 |
| NR_003141 | SNHG4 | 2.58 | 0.046 |
| lnc-AC092031.1-1:11 | Inc-AC092031.1-1 | 2.54 | 0.037 |
| NM_001406 | EFNB3 | 2.51 | 0.042 |
| ENST00000370434 | ABCC2 | 2.51 | 0.041 |
| lnc-RPS6KA3-1:1 | lnc-RPS6KA3-1 | 2.49 | 0.042 |
| NM_001001953 | OR10G9 | 2.48 | 0.042 |
| AB007978 | KIAA0509 | 2.38 | 0.023 |
| NR_036536 | SNHG4 | 2.32 | 0.024 |
| NR_024014 | PP14571 | 2.32 | 0.049 |
| NM_032598 | SPATA22 | 2.32 | 0.031 |
| lnc-TAF15-1:1 | lnc-TAF15-1 | 2.28 | 0.049 |
| NM_005810 | KLRG1 | 2.28 | 0.034 |
| NM_004750 | CRLF1 | 2.25 | 0.045 |
| lnc-AC007557.1.1-3:2 | lnc-AC007557.1.1-3 | 2.25 | 0.043 |
| NR_033791 | DOC2GP | 2.24 | 0.031 |
| NM_033119 | NKD1 | 2.23 | 0.037 |
| NM_001005610 | EDA | 2.20 | 0.047 |
| ENST00000374186 | DHDDS | 2.19 | 0.041 |
| lnc-PPT1-1:1 | lnc-PPT1-1 | 2.18 | 0.044 |
| lnc-TRMT11-1:1 | Inc-TRMT11-1 | 2.16 | 0.028 |
| lnc-BTBD10-3:10 | Inc-BTBD10-3 | 2.12 | 0.048 |
| NR_026704 | VTRNA1-2 | 2.12 | 0.035 |
| NM_175630 | DNMT3A | 2.11 | 0.021 |
| ENST00000617024 | SPTSSB | 2.11 | 0.032 |
| NR_038287 | TEX26-AS1 | 2.11 | 0.039 |
| NM_198501 | SMTNL2 | 2.10 | 0.045 |
| lnc-AC092031.1-1:8 | Inc-AC092031.1-1 | 2.09 | 0.040 |
| NM_006209 | ENPP2 | 2.08 | 0.036 |
| BI056255 | BI056255 | 2.07 | 0.045 |
| lnc-NSMAF-1:1 | Inc-NSMAF-1 | 2.05 | 0.021 |
| NM_003619 | PRSS12 | 2.04 | 0.048 |
| ENST00000392645 | ATXN2 | 2.04 | 0.045 |
| NM_203486 | DLL3 | 2.03 | 0.028 |
| ENST00000605570 | ENST0000605570 | 2.01 | 0.042 |
| NM_001005463 | EBF3 | 2.01 | 0.034 |
| THC2682558 | THC2682558 | 2.01 | 0.030 |
| NM_024534 | ERVMER34-1 | 2.00 | 0.043 |
| NR_036446 | ACTG1P17 | -2.01 | 0.049 |
| lnc-CCDC40-1:1 | lnc-CCDC40-1 | -2.01 | 0.045 |

| lnc-MINA-3:1 | Inc-MINA-3 | -2.02 | 0.027 |
|-------------------------|-----------------------|-------|-------|
| lnc-KANK4-1:1 | lnc-KANK4-1 | -2.03 | 0.031 |
| THC2701566 | THC2701566 | -2.06 | 0.030 |
| ENST00000427341 | ENST00000427341 | -2.07 | 0.043 |
| NM_001110199 | SRRM3 | -2.07 | 0.038 |
| NM_012114 | CASP14 | -2.07 | 0.035 |
| NM_021026 | RFPL1 | -2.10 | 0.037 |
| NM_033317 | DMKN | -2.10 | 0.049 |
| lnc-RGL4-4:2 | lnc-RGL4-4 | -2.11 | 0.039 |
| Inc-TELO2-3:1 | Inc-TELO2-3 | -2.13 | 0.049 |
| ENST00000421673 | MUC6 | -2.13 | 0.046 |
| lnc-NDE1-3:1 | Inc-NDE1-3 | -2.15 | 0.046 |
| NM_003027 | SH3GL3 | -2.15 | 0.022 |
| lnc-RP11-150012.3.1-3:1 | lnc-RP11-150012.3.1-3 | -2.15 | 0.043 |
| NM_001002294 | FMO3 | -2.16 | 0.039 |
| ENST00000538329 | ENST00000538329 | -2.16 | 0.044 |
| NR_001296 | PRSS3P2 | -2.18 | 0.037 |
| NM_000478 | ALPL | -2.20 | 0.033 |
| NR_030732 | WFDC21P | -2.22 | 0.043 |
| lnc-NAA35-1:2 | Inc-NAA35-1 | -2.22 | 0.042 |
| Inc-SALL3-2:1 | Inc-SALL3-2 | -2.23 | 0.048 |
| ENST00000528496 | LOC101928823 | -2.23 | 0.036 |
| ENST00000517994 | ENST00000517994 | -2.23 | 0.033 |
| lnc-ID4-1:1 | lnc-ID4-1 | -2.24 | 0.039 |
| NM_001171832 | DEFB121 | -2.24 | 0.023 |
| THC2674454 | THC2674454 | -2.25 | 0.033 |
| A_33_P3351791 | A_33_P3351791 | -2.25 | 0.045 |
| lnc-LRP11-1:1 | Inc-LRP11-1 | -2.25 | 0.018 |
| NM_001650 | AQP4 | -2.27 | 0.045 |
| NM_001017915 | INPP5D | -2.28 | 0.025 |
| Inc-TGFBRAP1-11:1 | Inc-TGFBRAP1-11 | -2.29 | 0.032 |
| NR_040094 | LINC01193 | -2.30 | 0.045 |
| CU688821 | CU688821 | -2.31 | 0.044 |
| NM_018995 | MOV10L1 | -2.32 | 0.045 |
| NM_001003954 | ANXA13 | -2.36 | 0.045 |
| TCONS_12_00014098 | XLOC_12_007656 | -2.37 | 0.042 |
| NM_014725 | STARD8 | -2.37 | 0.047 |
| ENST00000450729 | ENST00000450729 | -2.37 | 0.024 |
| lnc-MFAP4-4:1 | Inc-MFAP4-4 | -2.39 | 0.045 |
| NM_032045 | KREMEN1 | -2.39 | 0.030 |
| TCONS_12_00009528 | XLOC_12_005020 | -2.40 | 0.043 |
| Inc-C5orf17-5:1 | lnc-C5orf17-5 | -2.41 | 0.047 |
| XR_433481 | LOC101927943 | -2.42 | 0.028 |
| NM_001105581 | LRRC30 | -2.42 | 0.032 |

| Inc-EBF3-1:1 | lnc-EBF3-1 | -2.43 | 0.048 |
|-----------------|-----------------|-------|-------|
| lnc-ITGA7-1:1 | lnc-ITGA7-1 | -2.44 | 0.043 |
| ENST00000517369 | ENST00000517369 | -2.47 | 0.042 |
| lnc-IDS-5:1 | lnc-IDS-5 | -2.50 | 0.038 |
| NM_017986 | SLC52A1 | -2.52 | 0.023 |
| AA378382 | SNORA12 | -2.52 | 0.037 |
| NR_024507 | LINC00598 | -2.53 | 0.020 |
| lnc-NME4-1:2 | lnc-NME4-1 | -2.53 | 0.033 |
| NM_000751 | CHRND | -2.54 | 0.040 |
| NM_001307 | CLDN7 | -2.54 | 0.029 |
| Inc-ITPR2-2:3 | Inc-ITPR2-2 | -2.54 | 0.041 |
| NM_000337 | SGCD | -2.56 | 0.039 |
| Inc-ACOT12-2:1 | Inc-ACOT12-2 | -2.56 | 0.042 |
| NR_003062 | SPRR2C | -2.58 | 0.034 |
| Inc-LENG9-2:1 | Inc-LENG9-2 | -2.59 | 0.043 |
| lnc-SGCG-5:1 | Inc-SGCG-5 | -2.59 | 0.043 |
| NM_001001850 | STX19 | -2.60 | 0.049 |
| lnc-RNF152-1:1 | Inc-RNF152-1 | -2.64 | 0.022 |
| NM_004205 | USP2 | -2.65 | 0.048 |
| AK096685 | AK096685 | -2.69 | 0.032 |
| lnc-TRUB2-2:1 | Inc-TRUB2-2 | -2.70 | 0.045 |
| A_21_P0014374 | A_21_P0014374 | -2.70 | 0.031 |
| AK127488 | LOC100130429 | -2.71 | 0.048 |
| NM_032648 | FAM167B | -2.73 | 0.039 |
| A_33_P3368445 | A_33_P3368445 | -2.74 | 0.030 |
| NM_020630 | RET | -2.74 | 0.046 |
| Inc-MTERFD3-2:1 | Inc-MTERFD3-2 | -2.82 | 0.023 |
| ENST00000572608 | LOC102723363 | -2.83 | 0.048 |
| ENST00000510838 | ENST00000510838 | -2.84 | 0.049 |
| NM_001078 | VCAM1 | -2.84 | 0.046 |
| NR_122070 | LOC729083 | -2.85 | 0.038 |
| lnc-RXFP4-1:1 | lnc-RXFP4-1 | -2.89 | 0.030 |
| NM_032411 | C2orf40 | -2.91 | 0.044 |
| NR_033312 | BDNF-AS | -2.92 | 0.035 |
| ENST00000578788 | ENST00000578788 | -2.94 | 0.042 |
| A_33_P3417547 | A_33_P3417547 | -2.95 | 0.045 |
| XR_241421 | LOC101928662 | -2.96 | 0.038 |
| lnc-LRRTM2-1:1 | Inc-LRRTM2-1 | -2.99 | 0.045 |
| NR_120410 | LMO7-AS1 | -3.04 | 0.035 |
| NM_024889 | PLEKHS1 | -3.09 | 0.050 |
| A_33_P3351166 | A_33_P3351166 | -3.09 | 0.046 |
| CA436475 | SNAR-E | -3.14 | 0.021 |
| lnc-CDYL2-6:5 | lnc-CDYL2-6 | -3.15 | 0.034 |
| ENST00000585853 | PSMG2 | -3.18 | 0.048 |

| TCONS_12_00008966 | XLOC_12_004857 | -3.19 | 0.039 |
|-------------------|-----------------|-------|-------|
| NM_001038 | SCNN1A | -3.27 | 0.035 |
| NM_021175 | HAMP | -3.30 | 0.026 |
| ENST00000421132 | ENST00000421132 | -3.34 | 0.032 |
| NR_026836 | TRHDE-AS1 | -3.40 | 0.034 |
| Inc-TMTC4-1:1 | Inc-TMTC4-1 | -3.54 | 0.043 |
| Inc-EN1-1:1 | lnc-EN1-1 | -3.61 | 0.025 |
| Inc-EEA1-1:2 | Inc-EEA1-1 | -3.93 | 0.034 |
| Inc-ADAMTS17-1:6 | Inc-ADAMTS17-1 | -3.95 | 0.027 |
| THC2570812 | THC2570812 | -3.97 | 0.045 |
| NM_005755 | EBI3 | -4.01 | 0.035 |
| Inc-FAM27D1.1-3:1 | Inc-FAM27D1.1-3 | -4.07 | 0.020 |
| NM_016150 | ASB2 | -4.09 | 0.029 |
| NM_001145121 | TCP10L2 | -4.16 | 0.040 |
| ENST00000433724 | ENST00000433724 | -4.21 | 0.035 |
| A_33_P3809328 | A_33_P3809328 | -4.41 | 0.045 |
| NM_001145641 | SRRM5 | -4.71 | 0.028 |
| Inc-GLB1L2-1:11 | lnc-GLB1L2-1 | -4.80 | 0.045 |
| Inc-WNT7A-1:3 | lnc-WNT7A-1 | -5.07 | 0.037 |
| THC2715267 | THC2715267 | -5.29 | 0.032 |
| ENST00000426418 | ENST00000426418 | -9.16 | 0.019 |
| | | | |

| Ingenuity Canonical Pathways | -log(p-value) | Ratio | Molecules |
|---|---------------|----------|----------------------------------|
| Insulin Receptor Signaling | 2.92E+00 | 2.84E-02 | SCNN1A, PPP1R14C, BAD, INPP5D |
| Dolichol and Dolichyl Phosphate Biosynthesis | 2.18E+00 | 5.00E-01 | DHDDS |
| UDP-N-acetyl-D-glucosamine Biosynthesis II | 1.71E+00 | 1.67E-01 | FMO3 |
| Ceramide Biosynthesis | 1.64E+00 | 1.43E-01 | SPTSSB |
| IL-3 Signaling | 1.51E+00 | 2.41E-02 | BAD, INPP5D |

1.3. Table S3. Top five pathways of 192 DEGs in HCC mice treated with high dose of ascorbate by IPA analysis.

2. Supplemental Figures:

2.1. Figure S1. Soft-agar assay of Huh-7 and LO2 cells treated with ascorbate for 14-21 days. A) Huh-7 cells; B) LO2 cells.



2.2. Figure S2. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of these differentially expressed mRNAs was performed to determine the top 30 pathways of the differential mRNAs in HCC tumour tissue from mice treated with IP injection of ascorbate at 2.0 g/kg/3 days (A) and 4.0 g/kg/3 days (B) compared with expression in their controls.



2.3. Figure S3. PET/CT scan images of the patients of middle age woman with massive primary cancer of the liver (hepatocellular carcinoma) with 4treatments of HiCLoChemo (B), compared with her PET/CT scan done before the start of treatment (A).



A

B

2.4. Figure S4. The description of the generation of the ascorbate in animals and plants which can synthesize ascorbate through a sequence of enzyme-driven steps involving in the converting monosaccharides to ascorbate.

